(Q34091095)

30 July 2017

title

EFNS guideline on the management of status epilepticus in adults (English)

1 reference

European Federation of Neurological Societies

30 July 2017

1 reference

8

object named as

European Federation of Neurological Societies

1 reference

30 July 2017

H Meierkord

1

1 reference

30 July 2017

P Boon

2

1 reference

30 July 2017

B Engelsen

3

1 reference

30 July 2017

K Göcke

4

1 reference

30 July 2017

S Shorvon

5

1 reference

30 July 2017

P Tinuper

6

1 reference

30 July 2017

M Holtkamp

7

1 reference

30 July 2017

publication date

30 December 2009

1 reference

European Journal of Neurology

30 July 2017

published in

1 reference

30 July 2017

volume

17

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

348-355

1 reference

Incidence of status epilepticus in adults in Germany: a prospective, population-based study

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Incidence and short-term prognosis of status epilepticus in adults in Bologna, Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

In-hospital mortality of generalized convulsive status epilepticus: a large US sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Status epilepticus: pathophysiology and management in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Basic mechanisms of generalized absence seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Status epilepticus: risk factors and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

How long do most seizures last? A systematic comparison of seizures recorded in the epilepsy monitoring unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

It's time to revise the definition of status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Refractory status epilepticus: frequency, risk factors, and impact on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Non-convulsive status epilepticus in adults: clinical forms and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Propofol and midazolam in the treatment of refractory status epilepticus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Use of midazolam in the treatment of refractory status epilepticus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Double-blind Study of Lorazepam and Diazepam in Status Epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus--experience in 102 adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Systemic effects of generalized convulsive status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Transient loss of inhibition precedes spontaneous seizures after experimental status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Halothane as a neuroprotectant during constant stimulation of the perforant path.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

No, some types of nonconvulsive status epilepticus cause little permanent neurologic sequelae (or: "the cure may be worse than the disease").

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

A "malignant" variant of status epilepticus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

The management of refractory generalised convulsive and complex partial status epilepticus in three European countries: a survey among epileptologists and critical care neurologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Continuous infusion of midazolam in the treatment of refractory generalized convulsive status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Propofol in the treatment of refractory status epilepticus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Refractory status epilepticus: effect of treatment aggressiveness on prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

Ketamine successfully terminates malignant status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

The drug treatment of status epilepticus in Europe: Consensus document from a workshop at the first London Colloquium on Status Epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02917.X

10.1111/J.1468-1331.2009.02917.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference